Bugat, Mehada M.
HRN: 21-67-08 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/23/2022
CO-AMOXICLAV 625MG (TAB)
10/23/2022
10/30/2022
PO
625 BID
BID
Herniorrhaphy
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes